文献速递妇科肿瘤

莫托利莫德联合聚乙二醇脂质体多柔比星化疗-免疫治疗复发性或持续性卵巢癌的2期随机双盲安慰剂对照研究:妇科肿瘤学组合作研究

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
PubMed 文献 · Ann Oncol · 2017-01-01

该2期随机双盲安慰剂对照试验在复发性上皮性卵巢癌女性中评估莫托利莫德(TLR8激动剂)联合聚乙二醇脂质体多柔比星(PLD)的疗效与安全性。莫托利莫德联合PLD未显著改善总生存(单侧P=0.923,HR=1.22)或无进展生存(单侧P=0.943,HR=1.21)。预设亚组分析中,出现注射部位反应的莫托利莫德治疗患者死亡风险较低,且治疗前体外免疫生物标志物对TLR8刺激的反应可预测总生存。

要点

  • 莫托利莫德联合PLD未显著改善复发性卵巢癌患者的总生存和无进展生存。
  • 联合方案耐受性良好,未出现协同或非预期严重毒性。
  • 出现注射部位反应的患者死亡风险较低,治疗前体外免疫反应可预测总生存。

核心结论

  • 莫托利莫德联合PLD与安慰剂相比未改善临床结局。
  • 亚组分析发现,莫托利莫德治疗患者中根据注射部位反应和体外免疫反应的总生存差异有统计学意义。
  • 这些数据可能为识别适合免疫调节剂新联合方案和/或给药方式的患者提供重要线索。

研究设计与样本

  • 2期随机双盲安慰剂对照试验。
  • 研究对象为卵巢、输卵管或原发性腹膜癌女性。
  • 按1:1随机接受PLD联合盲法莫托利莫德或安慰剂。
  • 随机分层因素为铂类无治疗间期(≤6个月 vs >6-12个月)和妇科肿瘤学组体能状态(0 vs 1)。
  • 治疗周期每28天重复直至疾病进展。

主要发现

  • 莫托利莫德联合PLD未显著改善总生存(单侧对数秩检验P=0.923,HR=1.22)。
  • 莫托利莫德联合PLD未显著改善无进展生存(单侧对数秩检验P=0.943,HR=1.21)。
  • 联合方案耐受性良好,未出现协同或非预期严重毒性;多数患者出现疲乏、贫血、恶心、白细胞减少和便秘等不良事件。
  • 预设亚组分析中,出现注射部位反应的莫托利莫德治疗患者较未出现者死亡风险更低。
  • 治疗前体外免疫生物标志物对TLR8刺激的反应可预测接受莫托利莫德治疗患者的总生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death. PATIENTS AND METHODS: Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1 to receive PLD in combination with blinded motolimod or placebo. Randomization was stratified by platinum-free interval (≤6 versus >6-12 months) and Gynecologic Oncology Group (GOG) performance status (0 versus 1). Treatment cycles were repeated every 28 days until disease progression. RESULTS: The addition of motolimod to PLD did not significantly improve overall survival (OS; log rank one-sided P = 0.923, HR = 1.22) or progression-free survival (PFS; log rank one-sided P = 0.943, HR = 1.21). The combination was well tolerated, with no synergistic or unexpected serious toxicity. Most patients experienced adverse events of fatigue, anemia, nausea, decreased white blood cells, and constipation. In pre-specified subgroup analyses, motolimod-treated patients who experienced injection site reactions (ISR) had a lower risk of death compared with those who did not experience ISR. Additionally, pre-treatment in vitro responses of immune biomarkers to TLR8 stimulation predicted OS outcomes in patients receiving motolimod on study. Immune score (tumor infiltrating lymphocytes; TIL), TLR8 single-nucleotide polymorphisms, mutational status in BRCA and other DNA repair genes, and autoantibody biomarkers did not correlate with OS or PFS. CONCLUSIONS: The addition of motolimod to PLD did not improve clinical outcomes compared with placebo. However, subset analyses identified statistically significant differences in the OS of motolimod-treated patients on the basis of ISR and in vitro immune responses. Collectively, these data may provide important clues for identifying patients for treatment with immunomodulatory agents in novel combinations and/or delivery approaches. TRIAL REGISTRATION: Clinicaltrials.gov, NCT 01666444.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Monk BJ, Brady MF, Aghajanian C, et al. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol. 2017. PMID: 28453702. doi:10.1093/annonc/mdx049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。